Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics is seeking a synthetic chemist to advance their molecular glue degrader platform by designing proprietary small-molecule libraries targeting previously undruggable proteins. This role requires developing novel synthetic methodologies, overseeing global CRO networks, and integrating biological data to optimize drug discovery compounds.
Monte Rosa Therapeutics is a biotechnology company pioneering molecular glue degrader (MGD) therapies that promote specific protein ubiquitination and subsequent proteasomal degradation of disease-causing, traditionally undruggable proteins. Their drug discovery platform integrates expertise in MGD chemistry, artificial intelligence, structural biology, and proteomics to rapidly advance programs targeting undruggable or inadequately drugged targets with unprecedented specificity. Focused on cancer and beyond, the company operates out of Boston, MA and Basel, Switzerland.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc didn’t post a salary, so this is our estimate from similar listings.
5% below the average for this role
Synthetic Organic Chemist
Eli Lilly and Company
Scientist, Chemistry
Bristol Myers Squibb
Postdoctoral Researcher - Synthetic Medicinal Chemistry
University Health Network
Scientist, Medicinal Chemistry
Roche
Postdoctoral Researcher
University Health Network
Post-Doc Research Associate (Synthetic Chemistry -Heterocycles) - Frankowski Lab
PeopleAdmin